Performance Measurement for Opioid Use Disorder Medication Treatment and Care Retention.
作者信息
Williams Arthur Robin, Mauro Christine M, Feng Tianshu, Wilson Amanda, Cruz Angelo, Olfson Mark, Crystal Stephen, Samples Hillary, Chiodo Lisa
机构信息
Department of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center (Williams, Olfson); Columbia University Mailman School of Public Health (Mauro, Olfson); Research Foundation for Mental Hygiene, New York (Feng); Addiction Research and Education Foundation, Florence, Mass. (Wilson, Cruz); North-Star Care, Inc. Gig Harbor, Wash. (Wilson); Institute for Health, Health Care Policy, and Aging Research, Rutgers University, New Brunswick, N.J. (Crystal, Samples); University of Massachusetts Amherst, School of Nursing, Amherst, Mass. (Chiodo).
出版信息
Am J Psychiatry. 2023 Jun 1;180(6):454-457. doi: 10.1176/appi.ajp.20220456. Epub 2022 Oct 26.
Abstract
摘要
相似文献
1
Performance Measurement for Opioid Use Disorder Medication Treatment and Care Retention.阿片类物质使用障碍药物治疗及治疗持续率的绩效评估
Am J Psychiatry. 2023 Jun 1;180(6):454-457. doi: 10.1176/appi.ajp.20220456. Epub 2022 Oct 26.
2
Systematic review and meta-analysis of retention in treatment using medications for opioid use disorder by medication, race/ethnicity, and gender in the United States.美国药物治疗阿片类药物使用障碍的药物、种族/民族和性别与治疗保留的系统评价和荟萃分析。
Addict Behav. 2022 Jan;124:107113. doi: 10.1016/j.addbeh.2021.107113. Epub 2021 Sep 6.
3
Treating tobacco use disorder in pregnant women in medication-assisted treatment for an opioid use disorder: a systematic review.药物辅助治疗阿片类物质使用障碍时对孕妇烟草使用障碍的治疗：一项系统评价
J Subst Abuse Treat. 2015 May;52:40-7. doi: 10.1016/j.jsat.2014.12.002. Epub 2014 Dec 22.
4
Opioid agonist treatment for pharmaceutical opioid dependent people.用于药物性阿片类物质依赖者的阿片类激动剂治疗
Cochrane Database Syst Rev. 2016 May 9(5):CD011117. doi: 10.1002/14651858.CD011117.pub2.
5
Limited acceptance of buprenorphine in recovery residences in South Florida: A secret shopper survey.南佛罗里达州康复住所中丁丙诺啡的接受度有限：一项秘密购物者调查。
J Subst Use Addict Treat. 2025 Jan;168:209535. doi: 10.1016/j.josat.2024.209535. Epub 2024 Oct 5.
6
Retention of participants in medication-assisted programs in low- and middle-income countries: an international systematic review.低收入和中等收入国家药物辅助项目中参与者的留存率：一项国际系统评价
Addiction. 2014 Jan;109(1):20-32. doi: 10.1111/add.12303. Epub 2013 Aug 15.
7
Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal.经改良的 7 天缓释注射用丁丙诺啡治疗轻至中度阿片类药物戒断症状。
JAMA Netw Open. 2024 Jul 1;7(7):e2420702. doi: 10.1001/jamanetworkopen.2024.20702.
8
Health Services Usage in Patients Receiving Buprenorphine for Opioid Use Disorder or Long-Term Opioid Therapy for Chronic Pain: Retrospective Cohort Study.接受丁丙诺啡治疗阿片类物质使用障碍或长期阿片类药物治疗慢性疼痛患者的医疗服务利用情况：回顾性队列研究
JMIR Form Res. 2025 Jun 19;9:e66596. doi: 10.2196/66596.
9
10-year retention of a comprehensive treatment model of buprenorphine for opioid use disorder.丁丙诺啡综合治疗模式用于阿片类物质使用障碍的10年留存率
J Addict Dis. 2025 Jan-Mar;43(1):44-51. doi: 10.1080/10550887.2024.2315366. Epub 2024 Feb 24.
10
Effectiveness of methadone versus buprenorphine in the treatment of opioid use disorder: secondary analyses of prospective cohort study data.美沙酮与丁丙诺啡治疗阿片类物质使用障碍的有效性：前瞻性队列研究数据的二次分析
BMJ Open. 2025 Jun 17;15(6):e095645. doi: 10.1136/bmjopen-2024-095645.
引用本文的文献
1
Integrating HIV prevention services into care settings for people with opioid use disorder (OUD): a study protocol for implementation strategy development and modeling.将艾滋病毒预防服务纳入阿片类药物使用障碍（OUD）患者的护理环境：一项实施策略制定与建模的研究方案
Implement Sci Commun. 2025 Sep 1;6(1):93. doi: 10.1186/s43058-025-00782-1.
2
Are Treatment Services Ready for the Use of Big Data Analytics and AI in Managing Opioid Use Disorder?治疗服务机构是否准备好利用大数据分析和人工智能来管理阿片类药物使用障碍？
J Med Internet Res. 2025 Apr 28;27:e58723. doi: 10.2196/58723.
3
Advancing Health Equity Through Substance Use Medical Record Data Sharing: Insights from Healthcare Providers.通过物质使用病历数据共享促进健康公平：来自医疗保健提供者的见解。
Int J Environ Res Public Health. 2025 Mar 21;22(4):462. doi: 10.3390/ijerph22040462.
4
Development and validation of a pragmatic measure of context at the organizational level: The Inventory of Factors Affecting Successful Implementation and Sustainment (IFASIS).组织层面实用情境测量方法的开发与验证：影响成功实施与维持的因素量表（IFASIS）
Implement Sci Commun. 2025 Apr 25;6(1):50. doi: 10.1186/s43058-025-00726-9.
5
State sequence analysis of daily methadone dispensing trajectories among individuals at United States opioid treatment programs before and following COVID-19 onset.美国阿片类药物治疗项目中个体在新冠疫情爆发前后每日美沙酮配药轨迹的状态序列分析
Addiction. 2025 Jun;120(6):1207-1222. doi: 10.1111/add.70008. Epub 2025 Feb 26.
6
Exemplar Hospital Initiation Trial to Enhance Treatment Engagement (EXHIT ENTRE): protocol for CTN-0098 an open-label randomized comparative effectiveness trial of extended-release buprenorphine versus treatment as usual on post-hospital treatment engagement for hospitalized patients with opioid use disorder.提升治疗参与度的示范医院启动试验（EXHIT ENTRE）：CTN-0098方案，一项关于缓释丁丙诺啡与常规治疗对阿片类药物使用障碍住院患者出院后治疗参与度的开放标签随机对照有效性试验。
Addict Sci Clin Pract. 2024 Dec 2;19(1):91. doi: 10.1186/s13722-024-00510-5.
7
Predicting buprenorphine adherence among patients with opioid use disorder in primary care settings.预测初级保健环境中阿片类药物使用障碍患者对丁丙诺啡的依从性。
BMC Prim Care. 2024 Oct 11;25(1):361. doi: 10.1186/s12875-024-02609-9.
8
Buprenorphine discontinuation in telehealth-only treatment for opioid use disorder: A longitudinal cohort analysis.仅通过远程医疗治疗阿片类药物使用障碍时的丁丙诺啡停药：一项纵向队列分析。
J Subst Use Addict Treat. 2024 Dec;167:209511. doi: 10.1016/j.josat.2024.209511. Epub 2024 Sep 5.
9
Outpatient-Based Opioid Treatment Engagement and Attendance: A Prospective Cohort Study of Homeless-Experienced Adults.基于门诊的阿片类药物治疗参与和出勤率：一项针对有 homeless 经历的成年人的前瞻性队列研究。
J Gen Intern Med. 2024 Nov;39(15):2927-2934. doi: 10.1007/s11606-024-08916-2. Epub 2024 Jul 10.
10
US payment policy for medications to treat opioid use disorder: landscape and opportunities.美国治疗阿片类药物使用障碍药物的支付政策：现状与机遇
Health Aff Sch. 2024 Feb 27;2(3):qxae024. doi: 10.1093/haschl/qxae024. eCollection 2024 Mar.
本文引用的文献
1
Non-prescribed buprenorphine preceding treatment intake and clinical outcomes for opioid use disorder.非处方丁丙诺啡在阿片类药物使用障碍治疗前使用与临床结局。
J Subst Abuse Treat. 2022 Aug;139:108770. doi: 10.1016/j.jsat.2022.108770. Epub 2022 Mar 21.
2
Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis.阿片类激动剂治疗与阿片类药物依赖患者全因死亡率及特定死因的相关性：系统评价和荟萃分析。
JAMA Psychiatry. 2021 Sep 1;78(9):979-993. doi: 10.1001/jamapsychiatry.2021.0976.
3
Transforming Mental Health And Addiction Services.转型心理健康和成瘾服务。
Health Aff (Millwood). 2021 Feb;40(2):226-234. doi: 10.1377/hlthaff.2020.01472. Epub 2021 Jan 21.
4
Impact Of Long-Term Buprenorphine Treatment On Adverse Health Care Outcomes In Medicaid.美沙酮维持治疗对医疗补助不良医疗结果的影响。
Health Aff (Millwood). 2020 May;39(5):747-755. doi: 10.1377/hlthaff.2019.01085.
5
Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services.在美国全州接受阿片类药物使用障碍服务的人群中，阿片类激动剂治疗与致命性药物过量风险的关系。
Addiction. 2020 Sep;115(9):1683-1694. doi: 10.1111/add.14991. Epub 2020 Feb 24.
6
Trends in Buprenorphine Treatment in the United States, 2009-2018.2009-2018 年美国丁丙诺啡治疗趋势。
JAMA. 2020 Jan 21;323(3):276-277. doi: 10.1001/jama.2019.18913.
7
Acute Care, Prescription Opioid Use, and Overdose Following Discontinuation of Long-Term Buprenorphine Treatment for Opioid Use Disorder.急性治疗、处方阿片类药物使用以及在停止长期丁丙诺啡治疗阿片类药物使用障碍后出现的药物过量。
Am J Psychiatry. 2020 Feb 1;177(2):117-124. doi: 10.1176/appi.ajp.2019.19060612. Epub 2019 Dec 2.
8
Prescribing decisions at buprenorphine treatment initiation: Do they matter for treatment discontinuation and adverse opioid-related events?在丁丙诺啡治疗开始时的处方决策：它们对治疗停药和不良阿片类药物相关事件有影响吗？
J Subst Abuse Treat. 2019 Oct;105:37-43. doi: 10.1016/j.jsat.2019.07.010. Epub 2019 Jul 24.
9
Development of a Cascade of Care for responding to the opioid epidemic.开发一个应对阿片类药物流行的护理级联。
Am J Drug Alcohol Abuse. 2019;45(1):1-10. doi: 10.1080/00952990.2018.1546862. Epub 2019 Jan 24.
10
Promoting opioid overdose prevention and recovery: An exploratory study of an innovative intervention model to address opioid abuse.促进阿片类药物过量预防和康复：探索性研究一种创新的干预模式，以解决阿片类药物滥用问题。
Int J Drug Policy. 2019 Feb;64:21-29. doi: 10.1016/j.drugpo.2018.12.004. Epub 2018 Dec 12.
Zotero 插件